Roche’s Actemra Improves COVID-19 Survival, Study Claims

The Roche Group’s rheumatoid arthritis drug Actemra (tocilizumab) was found to reduce mortality and improve outcomes for high-risk COVID-19 patients, according to researchers from the UK’s Imperial College London.
Source: Drug Industry Daily